MAP2K7 and melanoma: Combined BRAF and MEK inhibitors therapy has emerged as an optimal treatment of metastatic BRAF-mutated melanoma, with improved survival rates compared with BRAF inhibitors alone (Dummer et al., 2022; Ascierto et al., 2020).